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ORIGINAL ARTICLE
Background/Aims: The increasing incidence of Candida glabrata and Candida krusei infections is a significant
problem because they are generally more resistant to fluconazole. We compared the risk factors associated with
C. glabrata and C. krusei fungemia with Candida albicans fungemia and examined the clinical manifestations
and prognostic factors associated with candidemia.
Methods: We retrospectively reviewed demographic data, risk factors, clinical manifestations, and outcomes
associated with C. glabrata and C. krusei fungemia at a tertiary-care teaching hospital during a 10-years period
from 1997 to 2006.
Results: During the study period, there were 497 fungemia episodes. C. glabrata fungemia accounted for 23
episodes and C. krusei fungemia accounted for 8. Complete medical records were available for 27 of these
episodes and form the basis of this study. Compared to 54 episodes of C. albicans fungemia, renal insufficiency
and prior fluconazole prophylaxis were associated with development of C. glabrata or C. krusei fungemia. The
overall mortality was 67%. The fungemia-related mortality of C. glabrata and C. krusei was higher than that of C.
albicans (52 vs. 26%, p=0.021). Empirical antifungal therapy did not decrease the crude mortality. Multiple logistic
regression analysis showed that high APACHE II scores, catheter maintenance, and shock were independently
associated with an increased risk of death.
Conclusions: Renal insufficiency and prior fluconazole prophylaxis were associated with the development of C.
glabrata or C. krusei fungemia. Fungemia-related mortality of C. glabrata or C. krusei was higher than that of C.
albicans. Outcomes appeared to be related to catheter removal, APACHE II scores, and shock. (Korean J Intern
Med 2009;24:263-269)
Keywords: Candidemia; Risk factors; Mortality
Received: April 3, 2008
Accepted: November 17, 2008
Correspondence to Jun Yong Choi, M.D.
Department of Internal Medicine, Yonsei University College of Medicine,134 Shinchon-dong, Seodaemun-gu, Seoul 120-792, Korea  
Tel: 82-2-2228-1975, Fax: 82-2-393-6884, E-mail: seran@yuhs.ac
INTRODUCTION
Recently, we have seen an increase in the frequency of
non-albicans species of Candida, such as C. glabrata, C.
krusei, C. tropicalis, and C. parapsilosis, as the cause of
fungemia [1,2]. C. krusei is intrinsically resistant to
fluconazole because of a decreased susceptibility of 14α-
demethylase [3], and C. glabrata is relatively resistant
to fluconazole due to an energy-dependent efflux mecha-
nism [4]. The increasing proportion of fungemia due to C.
glabrata and C. krusei has important implications for
therapy.
We evaluated the risk factors associated with C. glabrata
and C. krusei fungemia in comparison with Candida
albicans fungemia. We also examined the clinical
manifestations and prognostic factors associated with
candidemia.
METHODS
Study design
All episodes of fungemia that occurred between
January 1997 and December 2006 at Severance Hospital,
Yonsei University College of Medicine, Seoul, Korea, a
1500-bed tertiary-care teaching hospital, were identified.
We retrospectively reviewed demographic data, risk
factors, clinical manifestations, and outcomes associated
with C. glabrata and C. krusei fungemia. In addition, we
selected 54 patients who had C. albicans fungemia as the
control group. Cases and controls were matched 1 to 2 by
age, sex, and the time of fungemia.
Definitions
An episode of fungemia was defined as the isolation of
any pathogenic species of Candida from at least one blood
culture specimen from a patient with signs and symptoms
of infection. A second episode of fungemia occurring in
the same patient within 4 weeks of the first episode was
counted as the same episode. Recovery from candidemia
was defined as the resolution of all clinical manifestations
and no further positive blood cultures within 1 weeks after
therapy. Failure to respond was defined as the persistence
of clinical signs and symptoms or persistent candidemia
caused by the same Candida species after the onset of
therapy.
Death was attributed to Candida infection if the patient
did not respond to therapy and there was no other
obvious cause of death, such as a major hemorrhage or
other infection. We defined early mortality as death within
3 to 7 days after diagnosis and late mortality as death
between days 8 and 30. Patients who received no antifungal
therapy were excluded from the analysis.
Statistical analysis
The χ2 test and Fisher’s exact test were used to deter-
mine categorical predictors of infection and outcome.
Continuous variables were compared using the t-test.
Multiple logistic regression analysis was performed to
identify independent predictors of death; variables
included the APACHE II scores, catheter maintenance,
shock, non-albicans species, and early treatment. P values
of less than 0.05 were considered statistically significant.
All statistical analysis was performed with (SPSS Inc.,
Chicago, IL, USA).
RESULTS
Incidence, demographic and clinical characteristics
During the study period, there were 497 fungemia
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Figure 1. Annual fungemia episodes and causative organisms over a 10 year period at Severance Hospital.
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episodes. C. glabrata fungemia accounted for 23 episodes
(4.6%) and C. krusei fungemia accounted for eight
(1.6%). The proportion of fungemias due to C. glabrata
or C. krusei ranged from 0-29% per year (Fig. 1).
Complete medical records were available for 27 of the
31 episodes with non-albicans infections and 54 of the
234 episodes with C. albicans infections; therefore, 27
and 54 cases of each bloodstream infection were com-
pared.
Candida glabrata fungemia occurred in 12 men (44%
of subjects) and 15 women (56% of subjects). Their mean
age was 48±25 years. The majority of patients had multiple
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Table 1. Demographics, clinical manifestations, and risk factors of C. glabrata and C. krusei fungemia
C. glabrata or C. krusei C. albicans p value
(n=27) (n=54)
Age, years 48±25 49±23 NS
Male/female 12/15 12/15 NS
Underlying disease
Cardiovascular disease 9 (33) 19 (35) NS
Diabetes mellitus 10 (37) 16 (30) NS
Cirrhosis 2 (7) 4 (7) NS
Renal insufficiency 5 (19) 2 (4) 0.038
Dialysis 2 (7) 2 (4) NS
Autoimmune disease 0 (0) 3 (6) NS
Solid-organ cancer 9 (33) 19 (35) NS
Hematologic malignancy 5 (19) 5 (10) NS
Prematurity 1 (4) 2 (4) NS
Bone marrow transplant 1 (4) 2 (4) NS
Solid-organ transplant 0 (0) 1 (2) NS
HIV/AIDS 0 (0) 0 (0) NS
Radiotherapy 2 (7) 5 (9) NS
Immunosuppressive drugs 14(52) 23 (43) NS
Burns/trauma 2 (7) 5 (9) NS
Central venous catheter use 24 (89) 49 (91) NS
Parenteral nutrition 24 (89) 44 (82) NS
Mechanical ventilation 11 (41) 26 (48) NS
Prior major surgery, within 30 days 4 (15) 15 (28) NS
Neutropenia 5 (19) 7 (13) NS
Use of prophylactic fluconazole 12 (44) 6 (11) 0.001
Hospital days 67±50 77±72 NS
Hospital days before fungemia 38±33 42±47 NS
Stay in ICU, days 25±50 19±41 NS
Stay in ICU before fungemia, days 15±31 11±25 NS
APACHE II score 17±7 18±7 NS
Clinical manifestations
Endophthalmitis 0 (0) 0 (0) NS
Osteomyelitis 1 (4) 1 (2) NS
CNS infection 0 (0) 1 (2) NS
Endocarditis 0 (0) 1 (2) NS
Abscess 0 (0) 2 (4) NS
Peritonitis 4 (15) 6 (11) NS
Acute renal failure 11 (41) 21 (39) NS
Shock 18 (67) 27 (50) NS
Values are number (percentage) or mean±SD.
NS, not significant; HIV, human immunodeficiency virus; AIDS, acquired immune deficiency syndrome; ICU, intensive care unit ; CNS,
central nervous system.
underlying illnesses and other risk factors that have been
associated with fungemia. The most common underlying
illnesses were diabetes mellitus (37%), cardiovascular
diseases (33%), and solid-organ cancer (33%). No patient
developed endophthalmitis, central nervous system
infection, endocarditis, or abscesses during the follow-up
period. One patient had osteomyelitis and four had peri-
tonitis as a primary infection. Eleven patients developed
acute renal failure (ARF) and 18 presented with septic
shock (Table 1).
Risk factors for C. glabrata or C. krusei
Compared to 54 episodes of C. albicans fungemia,
renal insufficiency and prior fluconazole prophylaxis
were associated with the development of C. glabrata or
C. krusei fungemia (Table 1).
Treatment and outcomes of fungemia
Of the 27 episodes, 18 (67%) were treated with an
antifungal agent. Nine episodes (33%) were not treated
because of death before diagnosis (5 patients), discharge
to another hospital (1 patient), or no reason was docu-
mented (3 patients). Of the nine episodes for which an
antifungal agent was not used, two patients showed
recovery from the Candida infection. They were not
treated with any antifungal agent, but the central venous
catheter was removed. Of the 18 episodes for which an
antifungal agent was used, three were treated with
fluconazole alone, 13 episodes were treated with ampho-
tericin B formulation alone, and one case with osteo-
myelitis was treated with amphotericin B formulation
and surgery. One patient was treated with fluconazole
initially, and this was switched to amphotericin B after
the species was documented to be C. glabrata. For 10 of
the 13 episodes (77%) treated with amphotericin B,
additional blood cultures grew no yeast by the end of
therapy. The mortality rate for episodes treated with
amphotericin B was 54% (7 of 13 episodes), and fungemia
-related mortality constituted 23% (3 of 13 episodes). All
patients who did not achieve microbiological success
died of fungemia (Table 2).
Overall, the early and late mortality of C. glabrata and
C. krusei fungemia were not significantly different from
that due to C. albicans. However, the fungemia-related
mortality for C. glabrata and C. krusei was higher (52%,
14/27) than that due to C. albicans (26%, 14/54, p=0.021,
Table 3).
In the univariate analysis, patients whose central
venous catheters were not removed (p<0.01) or who had
high APACHE II scores (p=0.01) had a higher crude
mortality. Receiving appropriate antifungal therapy
within 24 hours was not associated with a risk of mortality
(p=0.21). Septic shock was associated with an increased
risk of mortality (p<0.01, Table 4).
Multiple logistic regression analysis showed that
increasing APACHE II scores (one-point increments)
(odds ratio [OR] 1.262, 95% CI 1.116-1.427, p<0.01),
catheter maintenance (OR 8.982, 95% CI 1.715-47.032,
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Table 2. Treatment outcomes of 27 episodes of C. glabrata and C. krusei
AmB Flu No treatment Op + AmB Flu + Am B
(n=13) (n=3) (n=9) (n=1) (n=1)
Recovery from candidemia 10 (77) 0 (0) 2 (22) 1 (100) 0 (0)
Mortality* 7 (54) 3 (100) 7 (78) 0 (0) 1 (100)
Fungemia-related mortality 3 (23) 3 (100) 7 (78) 0 (0) 1 (100)
Values are number (percentage).
AmB, amphotericin B; Flu, fluconazole; Op, operation.
* Overall mortality at day 30.
Table 3. Differences in outcome between C. glabrata, C. krusei, and C. albicans
C. glabrata or C. krusei C. albicans p value
(n=27) (n=54)
Recovery from candidemia 13 (48) 37 (69) 0.075
Mortality 18 (67) 26 (48) NS
Early mortality 4 (15) 11 (20)
Late mortality 14 (52) 15 (28)
Mortality related to fungemia 14 (52) 14 (26) 0.021
Values are number (percentage).
NS, not significant.
p<0.01), and shock (OR 14.465, 95% CI 3.573-58.557,
p<0.01) were independently associated with death
(Table 5).
DISCUSSION
Candida species are now the fourth most common
cause of nosocomial bloodstream infections and are
associated with a crude mortality rate of 39%, which is
the highest mortality rate associated with any form of
nosocomial bloodstream infection [1]. During the past
decade, an increase in the incidence of bloodstream
infections due to Candida species other than C. albicans
has been reported [2,5-7]. However, no increase in C.
glabrata or C. krusei fungemia was evident in our study.
Candida krusei and C. glabrata infections can cause
serious complications as they have higher crude mortality
than other Candida species, such as C. albicans or C.
parapsilosis [1]. In our study, non-albicans fungemia
did not cause complications such as endophthalmitis or
endocarditis. However, the true incidence of these compli-
cations is likely to have been higher, because echocardio-
graphy was performed in fewer than half of the episodes
and ophthalmological examinations were conducted in
five cases only. In our analysis, the crude mortality for
non-C. albicans (C. glabrata or C. krusei) fungemia was
not different from that due to C. albicans fungemia. This
is consistent with the findings of Klevay et al. [8], Blot et
al. [9], and Bassetti et al. [10], who found that mortality
did not differ by species. However, fungemia-related
mortality was significantly higher among patients with C.
glabrata or C. krusei fungemia.
Previous investigations have suggested that prior
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Table 4. Univariate analysis of the factors associated with death in patients with candidemia
Survivors Non-survivors p value
(n=37) (n=44)
Continuous variables
Age, years 52±23 44±24 NS
APACHE II score 21±6.7 14±5.4 0.01
Categorical variables
Catheter maintenance 5 (13.5) 19 (43.2) <0.01
Fluconazole prophylaxis 7 (18.9) 11 (25.0) NS
Early treatment (<24 hours) 13/35 (37.1) 9/37 (24.3) NS
Hypertension 10 (27.0) 18 (40.9) NS
Diabetes mellitus 10 (27.0) 16 (36.4) NS
Chronic renal failure 4 (10.8) 6 (13.6) NS
Autoimmune disease 1 (2.7) 2 (4.5) NS
Hematologic malignancy 3 (8.1) 7 (15.9) NS
Immunosuppressant 14 (37.8) 19 (43.2) NS
Solid cancer 13 (35.1) 15 (34.1) NS
Total parenteral nutrition 31 (83.8) 38 (86.4) NS
Non-albicans 9 (24.3) 18 (40.9) NS
Acute renal failure 11 (29.7) 21 (47.7) NS
Shock 10 (27.0) 34 (77.3) <0.01
Values are number (percentage) or mean±SD. 
NS, not significant.
Table 5. Multivariate analysis of the factors associated with death in patients with candidemia
OR 95% CI p value
APACHE II score (one-point increments) 1.26 1.11-1.42 <0.01
Catheter maintenance 9.14 1.69-49.53 0.01
Shock 14.68 3.54-60.86 <0.01
Non-albicans 1.26 0.32-5.00 0.746
Early treatment (<24 hours) 0.37 0.09-1.48 0.159
OR, odds ratio; CI, confidence interval.
exposure to antifungal agents [2,11,12], exposure to anti-
microbial agents, especially vancomycin or piperacillin-
tazobactam [13], age [14,15], and underlying hematologic
malignancy [11,16] were predisposing factors for non-
albicans fungemia.
Although there is a historical association between
fluconazole use and the increased incidence of relatively
resistant non-albicans Candida species, the degree to
which fluconazole plays a role in the risk to individual
patients remains unclear [17]. Fluconazole prophylaxis
was a predisposing factor in our analysis. However, not all
studies have linked fluconazole use to increased
colonization and infection by C. glabrata or C. krusei. Lin
et al. [13] reported that exposure to fluconazole was not
found to be a significant risk factor for developing non-C.
albicans candidemia. Similarly, Safdar et al. [18] reported
that the predominance of C. glabrata and C. krusei
breakthrough infections was similar to that seen with
high-dose fluconazole (400 mg) prophylaxis, and no
adverse effect of low-dose fluconazole in terms of an
increased incidence of non-susceptible Candida species
was seen.
In several studies, predictors of death from candidemia
were APACHE II scores at the time of fungemia [18-22],
length of hospitalization [23], delayed or inappropriate
treatment [21,24,25], neutropenia [19,20,26,27], and
central venous catheter maintenance [20,27]. We
observed that increasing APACHE II scores (OR 1.262,
95% CI 1.116-1.427, p<0.01), catheter maintenance (OR
8.982, 95% CI 1.715-47.032, p<0.01), and shock (OR
14.465, 95% CI 3.573-58.557, p<0.01) were independently
associated with the risk of death. This was similar to
previous studies, while empirical antifungal therapy,
which was started within 24 hours from the time when the
blood samples were obtained, but before identification of
the organism, did not improve outcome. Bias was likely in
the selection of antifungal agents used in various patients.
Immunocompromised patients were perhaps more likely to
have been given amphotericin B, and very sick patients
received no therapy because of early death due to fungemia.
There are several limitations to this study. First, data
were collected from a single center, resulting in a limited
sample size that could be influenced by local outbreaks,
specific infection-control practices, or regional suscepti-
bility patterns. Second, the retrospective nature of this
analysis may be susceptible to reviewer bias. Third, the
small sample size when various subsets were assessed
with regard to mortality precludes meaningful statistical
analysis of many of these factors.
In conclusion, renal insufficiency and prior fluconazole
prophylaxis were associated with the development of C.
glabrata or C. krusei fungemia. Fungemia-related mor-
tality due to C. glabrata or C. krusei was higher than due
to C. albicans.
The outcomes appeared to be related to catheter re-
moval, APACHE II scores, and shock. Future prospective
studies including data from multiple centers that analyze
antimicrobial use and subsequent colonization and
infection by C. glabrata and C. krusei will lead to a better
understanding of the epidemiology of these increasingly
important pathogens.
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